AB Science reports masitinib data in Phase II/III ALS trial
AB Science S.A. (Euronext:AB) reported additional data from the double-blind, Spanish Phase II/III Study AB10015 suggesting that the higher of 2 doses of oral masitinib (Masican, Masiviera) (AB1010) significantly slowed the progression of amyotrophic lateral sclerosis (ALS) vs. placebo in a subgroup of patients with more slowly progressing disease at baseline.
In March, the company said once-daily 4.5 mg/kg oral masitinib as an add-on to riluzole met the primary endpoint of improving ALS Functional Rating Scale-Revised (ALSFRS-R) score from baseline to week 48 vs. placebo plus riluzole (p=0.014). Patients received riluzole plus placebo or once-daily 3 or 4.5 mg/kg masitinib. AB Science said a stepwise sequence of analysis was predefined in the trial to first test the higher dose of masitinib vs. placebo and then the lower dose vs. placebo. The company said low-dose masitinib plus riluzole showed a trend toward improving ALSFRS-R score from baseline to week 48 vs. placebo plus riluzole (see BioCentury, April 18, 2016 & March 27, 2017). On May 18, the company presented the data at the European Network for the Cure of ALS meeting in Ljubljana, Slovenia...
BCIQ Company Profiles
BCIQ Target Profiles
Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117)